A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

---

Atıf İçin Kopyala

Hajek R., Pour L., ÖZCAN M., Sanchez J. M., Sanz R. G., Anagnostopoulos A., ...Daha Fazla

EUROPEAN JOURNAL OF HAEMATOLOGY, cilt.104, sa.5, ss.435-442, 2020 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 104 Sayı: 5
• Basım Tarihi: 2020
• Doi Numarası: 10.1111/ejh.13377
• Dergi Adı: EUROPEAN JOURNAL OF HAEMATOLOGY
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
• Sayfa Sayıları: ss.435-442
• Anahtar Kelimeler: bortezomib, dexamethasone, ibrutinib, multiple myeloma, BRUTON TYROSINE KINASE, TRIAL, MULTICENTER, THERAPY
• Ankara Üniversitesi Adresli: Evet

Özet

Objective We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies.